Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2018, Article ID 6872635, 11 pages
https://doi.org/10.1155/2018/6872635
Research Article

Circulating MicroRNAs in Elderly Type 2 Diabetic Patients

1Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy
2Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy
3Department of Biomedicine and Prevention, Tor Vergata University, Rome, Italy
4Fondazione Umberto Di Mario ONLUS, Rome, Italy
5Hypertension and Nephrology Unit, Department of Systems Medicine, Tor Vergata University, Rome, Italy

Correspondence should be addressed to Elisabetta Ferretti; ti.1amorinu@itterref.attebasile

Received 20 October 2017; Revised 25 January 2018; Accepted 18 February 2018; Published 10 April 2018

Academic Editor: Claudiane Guay

Copyright © 2018 Giuseppina Catanzaro et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Guay and R. Regazzi, “Circulating microRNAs as novel biomarkers for diabetes mellitus,” Nature Reviews Endocrinology, vol. 9, no. 9, pp. 513–521, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. N. Pescador, M. Pérez-Barba, J. M. Ibarra, A. Corbatón, M. T. Martínez-Larrad, and M. Serrano-Ríos, “Serum circulating microRNA profiling for identification of potential type 2 diabetes and obesity biomarkers,” PLoS One, vol. 8, no. 10, article e77251, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. T. Kubota, N. Kubota, and T. Kadowaki, “Imbalanced insulin actions in obesity and type 2 diabetes: key mouse models of insulin signaling pathway,” Cell Metabolism, vol. 25, no. 4, pp. 797–810, 2017. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Zhu and S. W. Leung, “Identification of microRNA biomarkers in type 2 diabetes: a meta-analysis of controlled profiling studies,” Diabetologia, vol. 58, no. 5, pp. 900–911, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. P. S. Mitchell, R. K. Parkin, E. M. Kroh et al., “Circulating microRNAs as stable blood-based markers for cancer detection,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 30, pp. 10513–10518, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Zampetaki, S. Kiechl, I. Drozdov et al., “Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes,” Circulation Research, vol. 107, no. 6, pp. 810–817, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. E. De Smaele, E. Ferretti, and A. Gulino, “MicroRNAs as biomarkers for CNS cancer and other disorders,” Brain Research, vol. 1338, pp. 100–111, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Ciccacci, R. Morganti, D. di Fusco et al., “Common polymorphisms in MIR146a, MIR128a and MIR27a genes contribute to neuropathy susceptibility in type 2 diabetes,” Acta Diabetologica, vol. 51, no. 4, pp. 663–671, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. D. Barbagallo, S. Piro, A. G. Condorelli et al., “miR-296-3p, miR-298-5p and their downstream networks are causally involved in the higher resistance of mammalian pancreatic α cells to cytokine-induced apoptosis as compared to β cells,” BMC Genomics, vol. 14, no. 1, p. 62, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Guay and R. Regazzi, “New emerging tasks for microRNAs in the control of β-cell activities,” Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, vol. 1861, no. 12, pp. 2121–2129, 2016. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Sebastiani, A. Po, E. Miele et al., “MicroRNA-124a is hyperexpressed in type 2 diabetic human pancreatic islets and negatively regulates insulin secretion,” Acta Diabetologica, vol. 52, no. 3, pp. 523–530, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. Z. Yang, H. Chen, H. Si et al., “Serum miR-23a, a potential biomarker for diagnosis of pre-diabetes and type 2 diabetes,” Acta Diabetologica, vol. 51, no. 5, pp. 823–831, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. P. C. Butler, S. Dry, and R. Elashoff, “GLP-1–based therapy for diabetes: what you do not know can hurt you,” Diabetes Care, vol. 33, no. 2, pp. 453–455, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. F. Wang, Y. He, R. Zhang, Q. Zeng, and X. Zhao, “Combination therapy of metformin plus dipeptidyl peptidase-4 inhibitor versus metformin plus sulfonylurea and their association with a decreased risk of cardiovascular disease in type 2 diabetes mellitus patients,” Medicine, vol. 96, no. 36, article e7638, 2017. View at Publisher · View at Google Scholar · View at Scopus
  15. M. de Souza Cazarim, E. L. C. da Cruz-Cazarim, A. de Oliveira Baldoni et al., “Cost-effectiveness analysis of different dipeptidyl-peptidase 4 inhibitor drugs for treatment of type 2 diabetes mellitus,” Diabetes & Metabolic Syndrome: Clinical Research & Reviews, vol. 11, Supplement 2, pp. S859–S865, 2017. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Mitrakou, “Pathogenesis of hyperglycaemia in type 2 diabetes,” Diabetes, Obesity and Metabolism, vol. 4, no. 4, pp. 249–254, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. Y.-G. Kim, D. Yoon, S. Park et al., “Dipeptidyl peptidase-4 inhibitors and risk of heart failure in patients with type 2 diabetes mellitus: a population-based cohort study,” Circulation: Heart Failure, vol. 10, no. 9, article e003957, 2017. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Monami, B. Ahrén, I. Dicembrini, and E. Mannucci, “Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials,” Diabetes, Obesity and Metabolism, vol. 15, no. 2, pp. 112–120, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. V. S. Bansal, C. P. Raja, K. Venkataraman, and M. Vijayalakshmi, “Genes involved in pancreatic islet cell rejuvenation,” The Indian Journal of Medical Research, vol. 137, no. 4, pp. 695–703, 2013. View at Google Scholar
  20. K. Kanasaki, S. Shi, M. Kanasaki et al., “Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen,” Diabetes, vol. 63, no. 6, pp. 2120–2131, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. M. B. Kirschner, J. J. B. Edelman, S. C. H. Kao, M. P. Vallely, N. van Zandwijk, and G. Reid, “The impact of hemolysis on cell-free microRNA biomarkers,” Frontiers in Genetics, vol. 4, p. 94, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. G. Catanzaro, Z. Besharat, N. Garg et al., “MicroRNAs-proteomic networks characterizing human medulloblastoma-SLCs,” Stem Cells International, vol. 2016, Article ID 2683042, 10 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  23. G. Giannini, C. Capalbo, L. Ottini et al., “Clinical classification of BRCA1 DNA missense variants: H1686Q is a novel pathogenic mutation occurring in the ontogenetically invariant THV motif of the N-terminal BRCT domain,” Journal of Clinical Oncology, vol. 26, no. 25, pp. 4212–4214, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. Y. He, Y. Ding, B. Liang et al., “A systematic study of dysregulated microRNA in type 2 diabetes mellitus,” International Journal of Molecular Sciences, vol. 18, no. 3, p. 456, 2017. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Zhu, N. Shyh-Chang, A. V. Segrè et al., “The Lin28/let-7 axis regulates glucose metabolism,” Cell, vol. 147, no. 1, pp. 81–94, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Bijkerk, J. M. G. J. Duijs, M. Khairoun et al., “Circulating microRNAs associate with diabetic nephropathy and systemic microvascular damage and normalize after simultaneous pancreas–kidney transplantation,” American Journal of Transplantation, vol. 15, no. 4, pp. 1081–1090, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Zhao, J. Guan, H. M. Lee et al., “Up-regulated pancreatic tissue microRNA-375 associates with human type 2 diabetes through β-cell deficit and islet amyloid deposition,” Pancreas, vol. 39, no. 6, pp. 843–846, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. C. Higuchi, A. Nakatsuka, J. Eguchi et al., “Identification of circulating miR-101, miR-375 and miR-802 as biomarkers for type 2 diabetes,” Metabolism, vol. 64, no. 4, pp. 489–497, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Wang, S. Wan, T. Yang et al., “Increased serum microRNAs are closely associated with the presence of microvascular complications in type 2 diabetes mellitus,” Scientific Reports, vol. 6, no. 1, article 20032, 2016. View at Publisher · View at Google Scholar · View at Scopus
  30. L.-l. Xu, C.-m. Shi, G.-f. Xu et al., “TNF-α, IL-6, and leptin increase the expression of miR-378, an adipogenesis-related microRNA in human adipocytes,” Cell Biochemistry and Biophysics, vol. 70, no. 2, pp. 771–776, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Zanutto, S. Pizzamiglio, M. Ghilotti et al., “Circulating miR-378 in plasma: a reliable, haemolysis-independent biomarker for colorectal cancer,” British Journal of Cancer, vol. 110, no. 4, pp. 1001–1007, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. V. Rottiers and A. M. Näär, “MicroRNAs in metabolism and metabolic disorders,” Nature Reviews Molecular Cell Biology, vol. 13, no. 4, pp. 239–250, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. F. J. Ortega, J. M. Mercader, J. M. Moreno-Navarrete et al., “Profiling of circulating microRNAs reveals common microRNAs linked to type 2 diabetes that change with insulin sensitization,” Diabetes Care, vol. 37, no. 5, pp. 1375–1383, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. Y. Liu, G. Gao, C. Yang et al., “The role of circulating microRNA-126 (miR-126): a novel biomarker for screening prediabetes and newly diagnosed type 2 diabetes mellitus,” International Journal of Molecular Sciences, vol. 15, no. 6, pp. 10567–10577, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. F. Olivieri, L. Spazzafumo, M. Bonafè et al., “miR-21-5p and miR-126a-3p levels in plasma and circulating angiogenic cells: relationship with type 2 diabetes complications,” Oncotarget, vol. 6, no. 34, pp. 35372–35382, 2015. View at Publisher · View at Google Scholar · View at Scopus
  36. Y. Zhao, Z. Yin, H. Li et al., “miR-30c protects diabetic nephropathy by suppressing epithelial-to-mesenchymal transition in db/db mice,” Aging Cell, vol. 16, no. 2, pp. 387–400, 2017. View at Publisher · View at Google Scholar · View at Scopus
  37. S. K. Raut, G. B. Singh, B. Rastogi et al., “miR-30c and miR-181a synergistically modulate p53–p21 pathway in diabetes induced cardiac hypertrophy,” Molecular and Cellular Biochemistry, vol. 417, no. 1-2, pp. 191–203, 2016. View at Publisher · View at Google Scholar · View at Scopus
  38. C. de Graaf, D. Donnelly, D. Wootten et al., “Glucagon-like peptide-1 and its class B G protein–coupled receptors: a long march to therapeutic successes,” Pharmacological Reviews, vol. 68, no. 4, pp. 954–1013, 2016. View at Publisher · View at Google Scholar · View at Scopus
  39. L. Ding, D. Ai, R. Wu et al., “Identification of the differential expression of serum microRNA in type 2 diabetes,” Bioscience, Biotechnology, and Biochemistry, vol. 80, no. 3, pp. 461–465, 2015. View at Publisher · View at Google Scholar · View at Scopus
  40. Y. O. Nunez Lopez, G. Garufi, and A. A. Seyhan, “Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes,” Molecular BioSystems, vol. 13, no. 1, pp. 106–121, 2017. View at Publisher · View at Google Scholar · View at Scopus
  41. J. A. Deiuliis, “MicroRNAs as regulators of metabolic disease: pathophysiologic significance and emerging role as biomarkers and therapeutics,” International Journal of Obesity, vol. 40, no. 1, pp. 88–101, 2016. View at Publisher · View at Google Scholar · View at Scopus